<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282525</url>
  </required_header>
  <id_info>
    <org_study_id>ECMOX1</org_study_id>
    <nct_id>NCT04282525</nct_id>
  </id_info>
  <brief_title>Monitoring of Cerebral Autoregulation in Pediatric ECMO (ECMOX 1)</brief_title>
  <acronym>ECMOX1</acronym>
  <official_title>Monitoring of Cerebral Autoregulation in Pediatric ECMO (ECMOX 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Istituto Giannina Gaslini</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children supported by Extra-Corporeal Membrane Oxygenation (ECMO) present a high risk of
      neurological complications and cerebral autoregulation (CA) impairment may be a risk factor.
      Our first objective is to investigate the feasibility of CA continuous monitoring during ECMO
      treatment. The second objective is to analyze the relationship between CA impairment and
      neurological outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients : All children treated by ECMO in the PICU of the Universitary hospital of Nantes,
      France and of IRCCS Giannina Gaslini Institute, Genoa, Italy

      Measurements: A correlation coefficient between the variations of regional cerebral oxygen
      saturation (rScO2) as a surrogate of cerebral blood flow and the variations of arterial blood
      pressure (ABP) is calculated as an index of autoregulation (cerebral oxygenation index (COx),
      ICM+ softwareÂ®). CA is monitored either on left (COxl) or both sides. A COx &gt; 0.3 is
      considered as critical. Neurological outcome is assessed by the onset of an acute neurologic
      event (ANE) during the ECMO run.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of continuous cerebral autoregulation monitoring</measure>
    <time_frame>12 hours before Extra-Corporeal Membrane Oxygenation</time_frame>
    <description>Percentage of time when cerebral autoregulation metrics are available. cerebral autoregulation metrics variations under Extra-Corporeal Membrane Oxygenation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of continuous cerebral autoregulation monitoring</measure>
    <time_frame>During Extra-Corporeal Membrane Oxygenation</time_frame>
    <description>Percentage of time when cerebral autoregulation metrics are available. cerebral autoregulation metrics variations under Extra-Corporeal Membrane Oxygenation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of continuous cerebral autoregulation monitoring</measure>
    <time_frame>12 hours after Extra-Corporeal Membrane Oxygenation</time_frame>
    <description>Percentage of time when cerebral autoregulation metrics are available. cerebral autoregulation metrics variations under Extra-Corporeal Membrane Oxygenation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between cerebral autoregulation metrics and neurological outcome</measure>
    <time_frame>12 hours after Extra-Corporeal Membrane Oxygenation</time_frame>
    <description>Correlation between the percentage of time spent in critical region of cerebral autoregulation and the onset of an acute neurological event (stroke and/or seizures and/or brain death) or not</description>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Extracorporeal Membrane Oxygenation Complication</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ECMO for hemodynamic or respiratory indication</intervention_name>
    <description>ECMO for hemodynamic or respiratory indication</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from 0 to 18 years treated by ECMO
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years treated by ECMO

        Exclusion Criteria:

          -  Lack of parental consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ECMO</keyword>
  <keyword>cerebral autoregulation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

